DBV Technologies S.A.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

Dear Fellow DBV Shareholders,

Each year, I begin my letter to you with the reminder that DBV was founded upon the belief that children living with food allergies, their families, and the clinicians who treat them need, and deserve, treatment options. That belief remains the core tenet of DBV today – it guides our corporate strategy as the Company progresses to commercialization with disciplined execution.

In recapping what has been a defining year for DBV, I must begin with the positive topline results from our Phase 3 VITESSE trial evaluating the VIASKIN® Peanut Patch in children aged 4 to 7 years. This result represents a milestone that the Company has worked towards over several years with passion. The VITESSE trial was designed with rigor and powered appropriately to support a successful outcome, reflecting the discipline of our development strategy and the careful execution of all those involved. The achievement of this milestone has provided the foundation required to advance the VIASKIN® Peanut Patch toward potential commercialization. We are on track to submit the Biologics License Application in the United States in the first half of this year.

In parallel, the Company made significant progress in the toddler population with the advancement of the COMFORT Toddlers supplemental safety trial of the VIASKIN® Peanut Patch in children aged 1 to 3 years. Through extensive and constructive dialogue with the U.S. Food and Drug Administration, the Company secured alignment on a path forward for this program and was able to have the first patient screened less than 4 months later. Notably, the eagerness of investigators and clinical sites to participate has been encouraging, and the interest we’ve seen from caregivers reinforces the unmet need for proactive treatment options in this patient population. The execution of the study, including the efficient management of rolling site activations, further demonstrates the Company’s operational capabilities and the discipline of its teams in advancing complex clinical programs.

Specifically, I’d like to highlight THRIVE. This first-of-its-kind study in infants aged 6 through 12 months, is designed to evaluate the VIASKIN® Peanut Patch to achieve adlib consumption or the ability to eat peanut freely. This first-of-its-kind study is an example of the Company’s continued commitment to the food allergy community and its pursuit to provide treatment options that have the potential to meaningfully change the trajectory and reduce the life-long burden of food allergy.

This commitment to advancing care is not only the right thing to do, it is increasingly aligned with the broader public health and regulatory environment. In February 2026, the U.S. Food and Drug Administration convened an expert panel on food allergies, bringing together scientific, clinical, and patient advocacy voices for a robust academic discussion on the current and future state of the field. The outcome highlighted the need for continued innovation and a greater emphasis on earlier intervention. It’s encouraging to hear these conversations further validate VIASKIN as a platform technology and the VIASKIN® Peanut Patch’s potential as a blockbuster product, once approved.

At the same time, the Company has continued to benefit from close and constructive engagement with the leading scientific, medical, and patient advocacy communities dedicated to advancing the understanding and management of food allergy. Through longstanding relationships with professional societies and advocacy organizations, DBV Technologies has remained an active participant in the ever-evolving dialogue shaping clinical practice and patient experience. The team has started to feature the robust results from VITESSE at recent medical conferences. Physicians and patient advocacy groups have received these results well and remain enthusiastic about the potential for our science to transform into an approved treatment option for patients.

DBV is still a clinical-stage biopharmaceutical company and as such may need additional funding to support its growth. Execution of the Company’s financing strategy is an important highlight of the past year. Through disciplined planning, strong investor engagement, and the ability of the leadership team to operate effectively under pressure, the Company raised $386.2 million in capital between March 2025 and January 2026. As disclosed in the Company’s Q1 2026 press release, this has provided the necessary funding to support its operations into the second quarter of 2027, including the potential US launch of the VIASKIN® Peanut Patch. The alignment between the Company and its investors, both new and old, on the near-term path to potential commercialization and the broader vision for the VIASKIN platform cannot be understated.

Looking ahead, DBV Technologies is poised to become a commercial company: it enters this period of growth and change supported by a strengthened financial position, expanded organizational capabilities, and a clear focus on disciplined execution. With conviction, DBV remains a champion of clinical science and to addressing the urgent unmet medical need that exists for food allergic patients and their families. The work we do matters and has impact. DBV is committed to bringing the VIASKIN® Peanut Patch to potential approval in the United States. As I have stated before, I state again: our confidence in the significant therapeutic and commercial potential of the VIASKIN® Peanut Patch, and in the broader VIASKIN technology platform, is unwavering.

Sincerely,

/s/ Michel de Rosen

Michel de Rosen

May 11, 2026

107 avenue de la République

92320 Châtillon France

NOTICE OF ANNUAL COMBINED GENERAL MEETING OF SHAREHOLDERS

To Be Held at 10:00 AM Paris Time on June 3, 2026

To the Shareholders of DBV Technologies S.A.:

The 2026 Annual Combined General Meeting of Shareholders of DBV Technologies S.A. (the “Company”), a French société anonyme, will be held on June 3, 2026, at 10:00 AM Paris time at the Company’s headquarters located at 107 avenue de la République 92320 Châtillon, France (the “2026 Annual General Meeting” or, more generally, the “Annual General Meeting”, the “General Meeting” or the “Meeting”).

On June 3, 2026, starting at 10:00 AM Paris time, the 2026 Annual General Meeting will be webcast with live audio on our website https://www.dbv-technologies.com. The recorded webcast of the 2026 Annual General Meeting will remain accessible on the Company’s website for at least the minimum legal and regulatory period from its publication online, following the date of the 2026 Annual General Meeting.

Within the authority of the extraordinary shareholders’ meeting:

40. Powers to complete formalities

These items of business are more fully described in the proxy statement accompanying this Notice.

These proxy materials will be mailed by Citibank, N.A. (the “Depositary”) commencing on May 12, 2026, to all holders of the Company’s American Depositary Shares (“ADSs”), each representing five ordinary shares of the Company, having a nominal value of €0.10 per share (the “Ordinary Shares” or “Shares”). Our registrar, Société Générale Securities Services, will commence mailing proxy materials to all holders of the Company’s Ordinary Shares on May 13, 2026.

In accordance with Article R.22-10-28 of the French Commercial Code, if you are a holder of Ordinary Shares that are registered in your name or in the name of an intermediary duly registered on your behalf as of May 27, 2026 at zero hour Paris time, which is the fifth business day prior to the meeting (the “Ordinary Share Record Date”), either in the registered share accounts or in the bearer share accounts held by their authorized intermediary, you will be eligible to vote your Ordinary Shares. You may (i) vote in person at the Annual General Meeting, (ii) grant your voting proxy directly to the Chairman of the Board of Directors, (iii) grant your voting proxy to another shareholder or to any other specifically designated person, (iv) vote by submitting your proxy card by mail or (v) vote by electronic mail via the secured platform Votaccess. Any shareholder who has already requested an admission card, sent a proxy, or cast a postal vote may no longer choose another means of participating in the Annual General Meeting.

If you hold ADSs, you may instruct the Depositary, either directly or through your broker, bank or other nominee, how to vote the Ordinary Shares underlying your ADSs. Please note that only holders of Ordinary Shares, and not ADS holders, are entitled to vote directly at the Annual General Meeting. The Depositary has fixed a record date for the determination of holders of ADSs who shall be entitled to give such voting instructions. We have been informed by the Depositary that it has set the ADS record date for the 2026 Annual General Meeting as April 23, 2026 (the “ADS Record Date”). If you wish to have your votes cast at the meeting, you must obtain, complete and timely return, at or prior to 10:00 AM (New York City time) on May 27, 2026, a voting instruction form from the Depositary, if you are a registered holder of ADSs, or from your broker, bank or other nominee in accordance with any instructions provided therefrom.

We appreciate your continued support of DBV Technologies S.A. and look forward to receiving your vote.

By order of the Board of Directors,

/s/ Daniel Tassé

Daniel Tassé

Chief Executive Officer

YOUR VOTE IS IMPORTANT. Please read the proxy statement and the accompanying materials. Whether or not you expect to attend the meeting, no matter how many Ordinary Shares or ADSs you own, please submit your proxy card or voting instruction form, as applicable, in accordance with the procedures described above.

Important Notice Regarding the Availability of Proxy Materials for the

2026 Annual General Meeting to be held on June 3, 2026:

The proxy statement and annual report are available on the Investors section of our website

https://www.dbv-technologies.com/investor-overview/sec-filings/

Our Depositary, Citibank, N.A., will commence mailing the proxy materials to all ADS holders on May 12, 2026. Our registrar, Société Générale Securities Services, will commence mailing the proxy materials to all holders of our Ordinary Shares on May 13, 2026.

Along with this proxy statement, we are also providing our 2025 annual report on Form 10-K (the “Annual Report”), which includes our financial statements prepared in accordance with U.S. GAAP for the fiscal year ended December 31, 2025.